Commentary: “Healthcare Professionals’ Preferred Efficacy Endpoints and Minimal Clinically Important Differences in the Assessment of New Medicines for Chronic Obstructive Pulmonary Disease” by Dankers M et al. in Frontiers in Pharmacology 2020; 10: 1519

Ejemplares similares

• Health status instruments for patients with COPD in pulmonary rehabilitation: defining a minimal clinically important difference
  por: Alma, Harma, et al.
  Publicado: (2016)
• Thresholds for clinically important deterioration versus improvement in COPD health status: results from a randomised controlled trial in pulmonary rehabilitation and an observational study during routine clinical practice
  por: Alma, Harma Johanna, et al.
  Publicado: (2019)
• The efficacy and safety of inhaled corticosteroids: are we ignoring the potential advantages of ciclesonide?
  por: van der Molen, Thys, et al.
  Publicado: (2014)
• Investigating sensitivity, specificity, and area under the curve of the Clinical COPD Questionnaire, COPD Assessment Test, and Modified Medical Research Council scale according to GOLD using St George’s Respiratory Questionnaire cutoff 25 (and 20) as reference
  por: Tsiligianni, Ioanna G, et al.
  Publicado: (2016)
• COPD management: role of symptom assessment in routine clinical practice
  por: van der Molen, Thys, et al.
  Publicado: (2013)